This fact sheet is for health professionals.
Administration of Zostavax to people who are immunocompromised is associated with risk of disseminated disease from the vaccine virus. As a result is is recommended that Zostavax not be administered to patients who are immunocompromised.
This fact sheet provides:
- contraindication details
- a guide to safe doses of immunosuppressive therapy for Zostavax administration
- immunisation contact details
- links to more information.
These files may not be suitable for users of assistive technology. Request an accessible format.